Cerezyme 400 U Powder for concentrate for solution for infusion

  • Name:

    Cerezyme 400 U Powder for concentrate for solution for infusion

  • Company:
    info
  • Active Ingredients:

    Imiglucerase

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 19/02/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 7/1/2019

Click on this link to Download PDF directly

Sanofi Genzyme

Sanofi Genzyme logo_1556886599

Company Products

Medicine NameActive Ingredients
Medicine Name Aldurazyme 100 U/ml concentrate for solution for infusion Active Ingredients Laronidase
Medicine Name AUBAGIO 14 mg film-coated tablets Active Ingredients Teriflunomide
Medicine Name Caprelsa 100mg and 300mg film coated tablets Active Ingredients Vandetanib
Medicine Name Cerdelga 84 mg capsules, hard Active Ingredients Eliglustat tartrate
Medicine Name Cerezyme 400 U Powder for concentrate for solution for infusion Active Ingredients Imiglucerase
Medicine Name Cholestagel 625mg film coated Tablets Active Ingredients Colesevelam hydrochloride
Medicine Name Dupixent 200 mg solution for injection in pre-filled pen Active Ingredients Dupilumab
Medicine Name Dupixent 300 mg solution for injection in pre-filled pen Active Ingredients Dupilumab
Medicine Name Evoltra 1 mg/ml concentrate for solution for infusion Active Ingredients Clofarabine
Medicine Name Fabrazyme 35 mg, powder for concentrate for solution for infusion Active Ingredients Agalsidase beta
Medicine Name Fabrazyme 5 mg, powder for concentrate for solution for infusion Active Ingredients Agalsidase beta
Medicine Name Fasturtec Active Ingredients Rasburicase
Medicine Name Fludara 50 mg powder for solution for injection or infusion Active Ingredients Fludarabine Phosphate
Medicine Name Fludara oral 10 mg film-coated tablets Active Ingredients Fludarabine Phosphate
Medicine Name LEMTRADA 12 mg concentrate for solution for infusion Active Ingredients Alemtuzumab
Medicine Name Mozobil 20 mg ml solution for injection Active Ingredients Plerixafor
Medicine Name Myozyme 50 mg, powder for concentrate for solution for infusion. Active Ingredients Alglucosidase alfa
Medicine Name Thymoglobuline 25 mg powder for solution for infusion Active Ingredients Rabbit Anti-Human Thymocyte Immunoglobulin
Medicine Name Thyrogen 0.9 mg powder for solution for injection Active Ingredients Thyrotropin alfa
1 - 0 of 19 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 19 February 2020 PIL

Reasons for updating

  • Change to section 6 - manufacturer

Updated on 24 December 2019 PIL

Reasons for updating

  • Change to section 6 - manufacturer

Updated on 11 October 2019 Ed-Both

Reasons for updating

  • Add New Doc

Updated on 11 October 2019 Ed-HCP

Reasons for updating

  • Add New Doc

Updated on 16 September 2019 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 25 February 2019 PIL

Reasons for updating

  • Change to section 5 - how to store or dispose
  • Change to section 6 - marketing authorisation holder

Updated on 7 January 2019 PIL

Reasons for updating

  • Change to section 5 - how to store or dispose
  • Change to section 6 - marketing authorisation holder

Updated on 7 January 2019 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

6.3     Shelf life

 

Unopened vials:

Cerezyme 200 Units powder for concentrate for solution for infusion

2 years

 

Cerezyme 400 Units powder for concentrate for solution for infusion

3 years

 

Diluted solution:

From a microbiological safety point of view, the product should be used immediately. If not used immediately, in-use storage and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2°C - 8°C under protection from light.

 

 

7.       MARKETING AUTHORISATION HOLDER

 

Genzyme Europe B.V., Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands

Updated on 21 December 2018 PIL

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - what the product contains
  • Change to section 6 - what the product looks like and pack contents

Updated on 19 December 2018 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

1.       NAME OF THE MEDICINAL PRODUCT

Cerezyme 200 Units Powder for concentrate for solution for infusion

Cerezyme 400 Units Powder for concentrate for solution for infusion

2.       QUALITATIVE AND QUANTITATIVE COMPOSITION

Cerezyme 200 Units powder for concentrate for solution for infusion

Cerezyme 400 Units powder for concentrate for solution for infusion

Cerezyme 200 Units powder for concentrate for solution for infusion

Cerezyme 400 Units powder for concentrate for solution for infusion

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

.3       Shelf life

Unopened vials:

Cerezyme 200 Units powder for concentrate for solution for infusion

2 years

Cerezyme 400 Units powder for concentrate for solution for infusion

2 3 years

.5       Nature and contents of container

Cerezyme is supplied in type I borosilicate (clear) glass 20 ml vials. The closure consists of a siliconised butyl stopper with a tamper proof flip-off cap.

Cerezyme 200 Units powder for concentrate for solution for infusion

Cerezyme 400 Units powder for concentrate for solution for infusion

Use Aseptic Technique

Reconstitution

Cerezyme 200 Units powder for concentrate for solution for infusion

Reconstitute each vial with 5.1 ml water for injections; avoid forceful impact of water for injections on the powder and, by mixing gently, avoid foaming of the solution. The reconstituted volume is 5.3 ml. The pH of the reconstituted solution is approximately 6.1.

Cerezyme 400 Units powder for concentrate for solution for infusion

Dilution

Cerezyme 200 Units powder for concentrate for solution for infusion

Cerezyme 400 Units powder for concentrate for solution for infusion

Updated on 27 April 2018 PIL

Reasons for updating

  • Improved presentation of PIL

Updated on 23 March 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 23 March 2018 PIL

Reasons for updating

  • Change to section 6 - date of revision
  • Change to other sources of information section

Updated on 17 August 2016 PIL

Reasons for updating

  • Change to improve clarity and readability
  • Addition of information on reporting a side effect.

Updated on 17 August 2016 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 8 - MA number
  • Change to improve clarity and readability

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8: Tabulated list of adverse reactions updated to a table that is more readable and reporting of side effects advisory to national competent authorities included.

Sections 2, 4.2, 4.3, 4.4, 4.6, 4.8, 5.1, 6.2, 6.4, 6.5, 6.6, and 8: Minor editorial updates to reflect the preferred terms according to the most recent MedDRA version (SmPC template).

Updated on 17 August 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 7 October 2014 PIL

Reasons for updating

  • Change to further information section

Updated on 30 August 2012 PIL

Reasons for updating

  • Removal/change of distributor

Updated on 2 June 2011 PIL

Reasons for updating

  • Change to further information section
  • Change to date of revision

Updated on 1 November 2010 SmPC

Reasons for updating

  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to sections:

 

 

6.6 Special precautions for disposal and other handling

 

Addition to sentence “It is recommended to administer the diluted solution through an in-line low protein-binding 0.2 µm filter to remove any protein particles. This will not lead to any loss of imiglucerase activity” this has been added under the ‘Dilution’ section and at the beginning of paragraph 2

 

10 Date of Revision of the Text

 

Change of date.

Updated on 1 November 2010 PIL

Reasons for updating

  • Change to date of revision
  • Change to further information section

Updated on 9 September 2010 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to further information section
  • Change to date of revision
  • Change to dosage and administration

Updated on 8 September 2010 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to sections:

 

4.2 Posology and method of administration

 

Deletion of “for Adults, Children & Elderly from header of “Posology”

Addition of “Paediatric population” – “No dose adjustment is necessary for the paediatric population”.

Addition of header “Method of Administration” plus addition of second paragraph under this header with the process for home infusion.

Addition of next paragraph – “For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6”

 

4.8 Undesirable effects

 

Change in table: "Respiratory symptoms" becomes “Dyspnoea, coughing”.  Addition to “Immune system disorders” section.  Addition of “*”,s

Change to paragraph under the table indicating the use of the “*”,s and the removal of the effects listed in the table above, a basic re-wording of the paragraph, also the removal of the first sentence regarding the undesirable effects on a small number of patients.

 

6.4 Special precautions for storage.

 

Addition to sentence – “For storage conditions of the diluted medicinal product, see section 6.3”

 

10 Date of Revision of the Text

 

Change of date.

Updated on 16 April 2010 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 16 April 2010 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided